Drug Database
Back to search

Ireland· IE-PA-EU/1/03/264/001

Zevalin

A ibritumomab tiuxetan 90y product containing ibritumomabum tiuxetan, registered in Ireland by Ceft Biopharma s.r.o. The same ATC class is registered in 7 of our 19 countries.

ATC V10XX02

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedZevalinATCV10XX02REGISTER NO.IE-PA-EU/1/03/264/001PACKS LISTED1CHECKEDSeptember 28, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ibritumomabum tiuxetanAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ibritumomab tiuxetan 90y is registered in 7 of 19 countries.

Countries holding a registration under ATC V10XX02 (ibritumomab tiuxetan 90y), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 5 of them publish a price we can compare per daily dose
Search ibritumomab tiuxetan 90y products by name

Ibritumomab tiuxetan 90y · ATC V10XX02

7 / 19 countries

  • Belgiumprice
  • Denmark
  • Finlandprice
  • Ireland
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

HPRA (Ireland)
Active substance
Ibritumomabum tiuxetan
Manufacturer
Ceft Biopharma s.r.o
Country
Ireland (IE)
ATC code
V10XX02
ATC class
Ibritumomab tiuxetan 90Y
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/03/264/001

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

199 interactions on record for ibritumomab tiuxetan 90y.

Graded by severity as the source publishes them — 127 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ibritumomab tiuxetan 90y against other medicinesHow interaction checks work

Ibritumomab tiuxetan 90y · interactions on record

199 records

  • 127 severe
  • 72 moderate

Most severe, free to view

  • DicoumarolB01AA01severe
  • WarfarinB01AA03severe
  • HeparinB01AB01severe
  • Antithrombin IIIB01AB02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ibritumomab tiuxetan 90y in 6 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ibritumomab tiuxetan 90y products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/88f410fb-442e-49ba-9e71-24ccfabbbea7
GET /v1/drugs/88f410fb-442e-49ba-9e71-24ccfabbbea7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Kit for radiopharmaceutical preparation",
  "routes": null,
  "source": "hpra",
  "atc_all": [
    "V10XX",
    "V10XX02"
  ],
  "strength": null,
  "pa_number": "EU/1/03/264/001",
  "substances": [
    "Ibritumomabum tiuxetan"
  ],
  "legal_basis": "New active substance (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": null,
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}
API referenceMCP serverPlans

See everything about ibritumomab tiuxetan 90y.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console